MS Speaks

As of September 7, 2016, there have been 685  confirmed Tysabri-related PML cases worldwide.  All but 3 of them have been people with MS. The other 3 are people with Crohn's disease.

As of August 31, 2016,  the overall PML incidence was 4.22 per 1000 patients (95% CI 3.91 to 4.55 per 1000 patients). 23% of the  patients have died. 77% of the patients are alive "with varying levels of disability."

As of June 30, 2016, roughly 156,500 patients received natalizumab (Tysabri) in  a post-marketing setting worldwide.

This information is from http://chefarztfrau.de/?page_id=716.